Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jacobs

Showing results (561-570 of 590) with videos related to

Pageof 59
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 1999
A profile of multiple sclerosis: the New York State Multiple Sclerosis ConsortiumL D Jacobs, K E Wende, C M Brownscheidle, et al.
American Journal of Infection Control|March 3, 2019
Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithmsSameer S Kadri, Jeffrey R Strich, Bruce J Swihart, et al.
Applied Optics|April 21, 2010
Large aperture harmonic conversion experiments at LLNL: commentsG J Linford, B C Johnson, J S Hildum, et al.
Advances in Radiation Oncology|June 15, 2026
Robustness of Tumor Control Against Intrafraction Patient Motion in Lung Stereotactic Body Radiation TherapyYohan A Walter, Chiachien J Wang, Daniel B Speir, et al.
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 13, 2009
Occult primary cancer clinical practice guidelinesDavid S Ettinger, Juan P Arnoletti, Jon P Gockerman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Occult primaryDavid S Ettinger, Mark Agulnik, Mihaela Cristea, et al.
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
Neurology|July 17, 1999
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)J H Simon, L D Jacobs, M K Campion, et al.
Pageof 59

Showing results (561-570 of 590) with videos related to

Sort By:
Pageof 59
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 1999
A profile of multiple sclerosis: the New York State Multiple Sclerosis ConsortiumL D Jacobs, K E Wende, C M Brownscheidle, et al.
American Journal of Infection Control|March 3, 2019
Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithmsSameer S Kadri, Jeffrey R Strich, Bruce J Swihart, et al.
Applied Optics|April 21, 2010
Large aperture harmonic conversion experiments at LLNL: commentsG J Linford, B C Johnson, J S Hildum, et al.
Advances in Radiation Oncology|June 15, 2026
Robustness of Tumor Control Against Intrafraction Patient Motion in Lung Stereotactic Body Radiation TherapyYohan A Walter, Chiachien J Wang, Daniel B Speir, et al.
Cancer|August 9, 2017
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)Aarti K Bhatia, Ju-Whei Lee, Harlan A Pinto, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 13, 2009
Occult primary cancer clinical practice guidelinesDavid S Ettinger, Juan P Arnoletti, Jon P Gockerman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Occult primaryDavid S Ettinger, Mark Agulnik, Mihaela Cristea, et al.
Neurology|May 22, 1998
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, N A Simonian, J A Alam, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2014
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunitRandal A Byrn, Steven M Jones, Hamilton B Bennett, et al.
Neurology|July 17, 1999
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)J H Simon, L D Jacobs, M K Campion, et al.
Pageof 59